Acutaas Chemicals Commissions OEB 4 High-Potency Intermediate Pilot Plant

en.Wedoany.com Reported - On September 4, Acutaas Chemicals officially commissioned a new pilot plant at its Unit-1 site in Sachin, Surat, Gujarat, India. A filing submitted by the company to the Indian stock exchange confirmed that the facility is intended for R&D trials and validation of new products, and includes a dedicated Occupational Exposure Band 4 high-containment operation area for the development and scale-up of high-potency chemical intermediates, which are subsequently used in the production of high-potency active pharmaceutical ingredients.

This commissioning marks a milestone in the capital expenditure project for Acutaas' previously announced Sachin pilot facility. According to the company's operating data for January 2026, capital expenditure for the nine months up to that point stood at approximately INR 1.43 billion, primarily directed toward the Jhagadia battery chemicals project and the Sachin pilot plant; at that time, the Sachin project had been delayed from its original schedule due to delays in equipment delivery. The official commissioning on September 4 signifies that this pilot facility, which was previously still in the equipment construction and installation phase, has now entered the operational stage.

The new pilot facility is directly integrated into Acutaas' existing Sachin manufacturing and R&D system. According to the company's annual data, the Sachin site currently operates 13 dedicated product lines, equipped with 40 reactors and 17 drying units, primarily for the production of advanced pharmaceutical intermediates; an R&D center is also located near the site, responsible for process development, analytical method development, synthesis, and process optimization. The new unit adds R&D trial, process validation, and scale-up capabilities, rather than constituting a new large-scale HPAPI production line with previously disclosed commercial capacity.

The existing quality and production systems at the Sachin site already cover pharmaceutical intermediate manufacturing. The company has disclosed that the site was inspected by the U.S. Food and Drug Administration in 2016 and 2019, and received corresponding inspection reports; in 2024, it also underwent an audit by Japan's PMDA. With the new pilot plant featuring an OEB 4 high-containment area, the site can now handle higher-potency intermediate development projects within its existing R&D–pilot–commercial production system.